Correlation Of Nf-Kappa B Signal Pathway With Tumor Metastasis Of Human Head And Neck Squamous Cell Carcinoma

Background: Nuclear factor-kappa B (NF-kappa B) signaling constitutes a key event in the multistep process of carcinogenesis, progression and treatment in many cancer types. However, the significance of NF-kappa B pathway for complex and tissue-specific aspects of head and neck cancer progression, such as invasion and metastasis, is less understood.Methods: The expression of NF-kappa B p65 in squamous cell carcinoma of the head and neck (SCCHN) clinical specimens by immunohistochemistry. The role of NF-kappa B activity in head and neck squamous cell carcinoma was determined by western blot, reporter assay and EMSA analysis in vitro and metastasis assays in vivo in different metastatic potential tumor cells. Furthermore, the apoptosis rate and expression of metastasis-related protein such as MMP9 and VEGF were examined by Annexin V/PI staining and Western blot, respectively.Results: A higher level of active nuclear-localized NF-kappa B was observed in the metastatic SCCHN specimens group (p < 0.01). The NF-kappa B activities of SCCHN cell lines with different metastatic potentials were then determined and in excellent agreement with results found in SCCHN specimens, highly metastatic SCCHN cell lines expressed high level of NF-kappa B activity. The treatment of highly metastatic SCCHN cells with NF-kappa B inhibitors reduced the in vitro cell invasion capacity of the cells without affecting the apoptotic rate. Additionally, the NF-kappa B inhibitors significantly inhibited the experimental lung metastasis of Tb cells and lymph node metastasis of TL cells in nude mice. Furthermore, the expression of metastasis-related proteins, such as matrix metalloproteinase 9 and vascular endothelial growth factor, was inhibited by pyrrolidine dithiocarbonate.Conclusions: This study suggests that NF kappa B activity significantly contributes to tumor hematologic and lymphatic metastases and may aid in the development of early detection methods or therapies targeting non-conventional molecular targets.